Visudyne (verteporfin; Valeant/Novartis) is a benzoporphyrin derivative photosensitizer developed for
use in photodynamic therapy.
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.
Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.
Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.
Verubecestat’s (Merck & Co) Phase Ib studies revealed highly impressive results in its capability to
almost abolish cerebrospinal fluid (CSF) amyloid-beta fragments.
Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound
Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway.
Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease.
Venetoclax (AbbVie/Roche) is a novel B-cell lymphoma-2 (BCL-2) inhibitor currently being developed
for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).
Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.
Veliparib is a small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AbbVie. PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events.
Velcade (bortezomib; Takeda/Johnson & Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death.
Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR).
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!